Results 221 to 230 of about 65,616 (255)
Some of the next articles are maybe not open access.

Increasing the Prescribing of Pre-Exposure Prophylaxis (PrEP) With a Pre-Exposure Prophylaxis Screening Tool

2022
Practice Problem: Human Immunodeficiency Virus (HIV) is one of the leading pandemics in the world. In 2019, 38 million people were living with HIV around the world. Of those, roughly 87% were aware of their HIV status. PICOT: In patients with high risk for HIV, how does implementing a pre-exposure (PrEP) screening tool compared to randomly screening ...
openaire   +1 more source

Pre-exposure prophylaxis in the perinatal period

The Lancet HIV
Women in sub-Saharan Africa are at high risk for HIV acquisition during pregnancy and postpartum periods, which puts the health of perinatal people at risk, but also contributes to new paediatric infections. Pre-exposure prophylaxis (PrEP) to prevent HIV is a highly effective intervention to prevent HIV acquisition.
Sheree, Schwartz, Friday, Saidi
openaire   +2 more sources

Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis

International Journal of STD & AIDS, 2015
Pre-exposure prophylaxis (PrEP) has been shown to reduce the risk of HIV transmission but has the potential to cause harm if not used properly. Pharmacists are well-positioned to foster PrEP’s efficacy but little is known whether they would endorse it as an HIV prevention tool.
Deborah, Yoong   +5 more
openaire   +2 more sources

Updates in pre-exposure prophylaxis for HIV

The Lancet Infectious Diseases, 2022
Ammara, Mushtaq, Farooq, Kazi
openaire   +2 more sources

The FACTS about women and pre-exposure prophylaxis

The Lancet HIV, 2015
The Editorial in the April issue, Antiretroival gels: facing the FACTS, describes the HIV community’s collective disappointment regarding the FACTS trial’s negative results. However, the conclusions that gels are not “practically feasible” and vaginal rings may be the “usable prevention strategy” that women need is misguided.
Dominika, Seidman   +4 more
openaire   +2 more sources

[Focus on pre-exposure prophylaxis].

Revue de l'infirmiere, 2013
Pre-exposure prophylaxis currently has no market authorisation in France, but is still evaluated. This article presents an additional tool for risk reduction, currently the subject of studies.
Emma, Torres, Jean-Luc, Meynard
openaire   +1 more source

Pre-Exposure Prophylaxis for HIV

American Journal of Preventive Medicine, 2013
James W. Curran, Richard A. Crosby
openaire   +2 more sources

Home - About - Disclaimer - Privacy